

Creating Global Solutions

AusBiotech2010
AUSTRALIA'S BIOTECHNOLOGY CONFERENCE

**National
Conference**

19 to 22 October 2010
Melbourne Convention and Exhibition Centre
www.ausbiotech2010.com.au

**Victoria
AUSTRALIA**

BioNet™
Asia Pacific

AUSBIOTECH 2010 NATIONAL CONFERENCE SPEAKERS' PROFILE

Karl D. Handelsman
Managing Director
CMEA Capital
United States

Karl Handelsman joined CMEA Capital in 1999. Karl has been involved with numerous CMEA investments such as: Ambrx, Ensemble Discovery, Ilypsa, Intellikine, Kalypsys, Maxygen, Phenomix, Rigel, Syrrx, Tetrphase, and Xenoport. Prior to joining CMEA, Karl was one of the first employees of Tularik, Inc., a drug discovery company, where his business development role spanned corporate partnering, technology licensing, and operations. Karl was also one of the first employees of Whitehead Institute, a premier research organization within Massachusetts Institute of Technology (MIT); and he worked in business development at Millennium Pharmaceuticals. Karl holds graduate degrees from both MIT and Harvard Medical School.

